Parnax Lab Limited (BOM:506128)

India · Delayed Price · Currency is INR

130.85

-3.50 (-2.61%)

At close: Sep 4, 2026

Market Cap	1.50B +0.5%
Revenue (ttm)	2.52B +31.9%
Net Income	89.34M -17.5%
EPS	7.78 -17.5%
Shares Out	11.49M
PE Ratio	16.81
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,973
Open	134.35
Previous Close	134.35
Day's Range	129.00 - 139.15
52-Week Range	99.20 - 182.00
Beta	0.03
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Parnax Lab

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provid... [Read more]

Industry Pharmaceutical Preparations

Founded 1982

Employees 12

Stock Exchange Bombay Stock Exchange

Ticker Symbol 506128

Full Company Profile

Financial Performance

In fiscal year 2026, Parnax Lab's revenue was 2.49 billion, an increase of 32.36% compared to the previous year's 1.88 billion. Earnings were 117.77 million, an increase of 2.24%.

Financial Statements